In patients with or without type 2 diabetes, efruxifermin treatment has consistently improved markers of glucose metabolism and insulin sensitivity while restoring a healthy lipoprotein profile without increasing body weight. The gene discussed is INS; the disease is type 2 diabetes mellitus.